Aflibercept biosimilar SB15 improved retinal anatomy while preserving vision in both treatment-naïve and switching patients with nAMD, RVO, and DME. Aflibercept 2 mg biosimilar SB15 (Afilivu; Samsung ...

Real-world natalizumab biosimilar switching preserved relapsing-remitting MS outcomes but lowered treatment satisfaction, likely due to a nocebo effect.

Real-world data shows rituximab biosimilars for membranous nephropathy match remission rates, cut costs, and expand treatment options. A lower-cost biosimilar of rituximab produced remission rates on ...

Early use of ustekinumab biosimilars in Spain shows cost-effective Crohn disease care, boosting QALYs and cutting NHS spend—insights for Europe. Patients with moderate to severe Crohn disease in Spain ...

Evidence suggests that adoption of oncology biosimilars in Medicare value-based payment models has produced substantial cost savings and improved provider financial performance. We estimate that ...

FDA approves new denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases while driving competition and cost savings. The US biosimilar market officially capped off a ...

Biosimilar development costs could plummet from $100 million to $5 million, enabling smaller companies to enter the market and revolutionize access to essential medicines. The biosimilars landscape is ...

FDA's new guidance clarifies promotional practices for biosimilars, ensuring accurate marketing and preventing misleading claims in the competitive landscape. The FDA has released comprehensive ...

Biosimilar denosumab offers significant cost savings and improved access to treatment, alleviating financial burdens in oncology care while enhancing patient outcomes. The rising cost of oncology care ...

FDA's new guidance streamlines biosimilar development, reducing costs and regulatory hurdles and potentially enhancing market access and affordability. The FDA has issued draft guidance that ...

Biosimilars and generics drive significant health care savings, yet a concerning lack of biosimilar development for biologics set to lose exclusivity in the next 10 years threatens future access and ...